Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIMERVAX Heterologous Booster in Adolescents
2023-504639-42-00Phase 2Completed
- Sponsor
- HIPRA
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by HIPRA. Primary endpoints: Neutralisation titre against Omicron BA.1 by PBNA (IC50, log10 GMT) at Baseline and Day 14, Solicited local and systemic reactions through Day 7 and 5 more. Started May 2023; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-504639-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504639-42-00.